Genprex GNPX Stock News

Genprex Inc (NASDAQ: GNPX), a company focused on the development of cancer drugs, is making the news again this morning. The company appeared on a audio broadcast discussing the biotechnology market as a whole. Here’s what’s happening:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

GNPX Earns Further Recognition

Genprex was recognized in an audio broadcast by NetworkNewsWire, according to a press release issued early this morning. According to the release, the broadcast was titled, “Record Revenues, Milestone Achievements Indicate Strength, Potential of Biotech Sector.”

To check out the publication, click here for the audio version or here for the text version.

A topic of conversation on the audio broadcast has to do with the significant milestones that GNPX is achieving. In the press release, NetworkNewsWire outlined the fact that the company is pressing forward with strategy objectives to “reprogram the course of cancer.”

Of course, the company plans on continuing to conduct its ongoing and new clinical trials with the goal of bringing new oncology options to market. The company is also in pursuit of strategic partnerships with organizations whose missions align well with that of GNPX.

One of these partnerships is with Aldevron. In fact, that partnership recently resulted in the successful completion of the manufacturing of the TUSC2 plasmid DNA.

The press release and broadcast also outlined the fact that the company is preparing to commercialize Oncoprex. Recently, the company announced the initiation of the first phase of branding the immunogene therapy. In particular, the company completed the creation and submission of nonproprietary drug name selections to the American Medical Associations’ United States Adopted Names Council.

What’s The Big Deal?

The truth of the matter is that Genprex is finally starting to receive the recognition that it deserves. Unfortunately, the company’s meaningful work with Oncoprex has largely gone unnoticed in recent years.

All while, the reality is that the treatment is proving to be effective across various cancer types and maintaining a favorable safety and tolerability profile in the process. All in all, this is a story that investors should be paying attention to, and with recent media recognition that the company deserves, the potential growth is being outlined for investors.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Don’t Miss The Next Big Story!

Join our mailing list below to receive free real-time news alerts!

Subscribe Today!

* indicates required


CNA Finance, parent company to Alpha Stock News, has been paid to cover Genprex news.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.